RU-24,969

From WikiMD's WELLNESSPEDIA

RU-24969_structure.png

Experimental drug

RU-24,969





Chemical nomenclature
IUPAC name 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane


















Chemical data


Chemical formula C11H17N1O2






RU-24,969 is an experimental drug that has been studied for its potential effects on the central nervous system. It is a member of the phenethylamine class of compounds and is structurally related to other psychoactive substances.

Chemical Structure and Properties[edit]

RU-24,969 is chemically known as 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane. It has a molecular formula of C11H17NO2. The compound features a phenyl ring substituted with two methoxy groups and a methyl group, along with an amino group attached to a propyl chain.

Pharmacology[edit]

The pharmacological profile of RU-24,969 suggests that it acts as a serotonin receptor agonist. It has been shown to have high affinity for the 5-HT2A receptor, which is implicated in the modulation of mood, perception, and cognition. The drug's interaction with this receptor is believed to underlie its psychoactive effects.

Research and Potential Applications[edit]

Research on RU-24,969 has primarily focused on its potential use in studying the serotonergic system and its role in various neuropsychiatric disorders. Studies have explored its effects on behavior, neurotransmitter release, and receptor binding in animal models. However, its use in humans has not been extensively studied, and it remains a compound of interest for further research.

Safety and Legal Status[edit]

As an experimental drug, RU-24,969 has not been approved for medical use. Its safety profile has not been fully established, and it is not regulated under any specific legal framework. Researchers handling this compound must adhere to appropriate safety protocols and regulatory guidelines.

See Also[edit]

References[edit]


Stub icon

This medical article is a stub. You can help WikiMD by expanding the page.


Sponsored Health Resource

W8MD weight loss success

W8MD Weight Loss, Sleep & MedSpa

Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.

GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.

Book a W8MD appointment · View GLP-1 specials

Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.

Retrieved from "https://wikimd.org/index.php?title=RU-24,969&oldid=5809373"